Azilsartan (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Azilsartan" in English language version.

refsWebsite

Global rank English rank

4^th place

4^th place

447^th place

338^th place

2web.archive.org

1^st place

1^st place

1,712^th place

1,063^rd place

2^nd place

2^nd place

68^th place

117^th place

399^th place

333^rd place

low place

low place

2,726^th place

1,608^th place

canada.ca

"Product monograph brand safety updates". Health Canada. February 2024. Retrieved 24 March 2024.

doi.org

Pradhan A, Tiwari A, Sethi R (2019). "Azilsartan: Current Evidence and Perspectives in Management of Hypertension". International Journal of Hypertension. 2019: 1824621. doi:10.1155/2019/1824621. PMC 6925743. PMID 31885897.

drugs.com

"Azilsartan medoxomil (Edarbi) Use During Pregnancy". Drugs.com. 28 February 2020. Retrieved 9 March 2020.

europa.eu

ema.europa.eu

"Edarbi EPAR". European Medicines Agency (EMA). 18 May 2018. Retrieved 9 March 2020.

fda.gov

fda.gov

"2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
"FDA approves Edarbi to treat high blood pressure" (Press release). U.S. Food and Drug Administration. 25 February 2011. Archived from the original on 18 January 2017. Retrieved 1 March 2011.

accessdata.fda.gov

"Drug Approval Package:Edarbyclor (azilsartan medoxomil and chlorthalidone) NDA #202331". U.S. Food and Drug Administration (FDA). 16 August 2012. Retrieved 11 March 2020.
"Drug Approval Package: Edarbi (azilsartan medoxomil) NDA 200796". U.S. Food and Drug Administration (FDA). 4 April 2011. Retrieved 9 March 2020.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision - Edarbi - Health Canada". Government of Canada. 26 June 2012. Retrieved 6 March 2021.

newswire.ca

"Valeant Canada acquires rights to Edarbi and Edarbyclor for the Canadian market" (Press release). Valeant Canada. 17 December 2014. Retrieved 9 March 2020 – via Cision.

nih.gov

pubmed.ncbi.nlm.nih.gov

Hardin MD, Jacobs TF (July 2021). "Azilsartan". StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID 30860708.
Pradhan A, Tiwari A, Sethi R (2019). "Azilsartan: Current Evidence and Perspectives in Management of Hypertension". International Journal of Hypertension. 2019: 1824621. doi:10.1155/2019/1824621. PMC 6925743. PMID 31885897.

dailymed.nlm.nih.gov

"Edarbi- azilsartan kamedoxomil tablet". DailyMed. 26 July 2019. Retrieved 9 March 2020.

ncbi.nlm.nih.gov

Pradhan A, Tiwari A, Sethi R (2019). "Azilsartan: Current Evidence and Perspectives in Management of Hypertension". International Journal of Hypertension. 2019: 1824621. doi:10.1155/2019/1824621. PMC 6925743. PMID 31885897.

web.archive.org

"2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
"FDA approves Edarbi to treat high blood pressure" (Press release). U.S. Food and Drug Administration. 25 February 2011. Archived from the original on 18 January 2017. Retrieved 1 March 2011.